| Tag |
First Indicator |
Second Indicator |
Subfields |
| LEADER |
00000cam a2200000 i 4500 |
| 001 |
in00005774882 |
| 005 |
20260327190427.8 |
| 006 |
m o d |
| 007 |
cr cnu---unuuu |
| 008 |
250519s2025 ne o 000 0 eng d |
| 040 |
|
|
|a OPELS
|b eng
|e rda
|e pn
|c OPELS
|d OCLCO
|d UKAHL
|d SFB
|
| 020 |
|
|
|z 9780443190889
|
| 035 |
|
|
|a (OCoLC)1520101057
|
| 050 |
|
4 |
|a RC346
|
| 082 |
0 |
4 |
|a 616.8
|2 23/eng/20250519
|
| 049 |
|
|
|a TXAM
|
| 245 |
0 |
0 |
|a Cholinergic involvement in neurodegenerative diseases /
|c edited by A. Claudio Cuello.
|
| 264 |
|
1 |
|a Amsterdam :
|b Elsevier,
|c 2025.
|
| 300 |
|
|
|a 1 online resource.
|
| 336 |
|
|
|a text
|b txt
|2 rdacontent
|
| 337 |
|
|
|a computer
|b c
|2 rdamedia
|
| 338 |
|
|
|a online resource
|b cr
|2 rdacarrier
|
| 490 |
0 |
|
|a Handbook of clinical neurology ;
|v volume 211
|
| 520 |
|
|
|a Cholinergic Involvement in Neurodegenerative Diseases, Volume 211 reviews cholinergic function in the brain as it relates to Neurodegenerative disorders. Coverage includes Alzheimer's, dementia, Down Syndrome, Parkinson's, Huntington's, ALS, and more. In addition, the anatomy of the cholinergic system is described as well as the distribution and function of receptors.
|
| 588 |
0 |
|
|a Online resource; title from PDF title page (ScienceDirect, viewed May 19, 2025).
|
| 505 |
0 |
|
|a Intro -- Cholinergic Involvement in Neurodegenerative Diseases -- Copyright -- Handbook of Clinical Neurology 3rd Series -- Foreword -- Preface -- Contributors -- Contents -- Chapter 1: A brief history of the CNS cholinergic transmission -- Introduction -- The Discovery of Acetylcholine as a Natural Substance -- Cholinesterase Inhibition and Bioassays Support the Concept of Cholinergic Neurotransmission -- The New Concept of Chemical Transmission of Nerve Impulses -- Acetylcholine Function in the CNS -- The Historical Significance of Cholinesterases -- The Chemical vs Electrical Transmission Controversy -- Chemical Neurotransmission at the Neuromuscular Junction -- Synaptic Vesicles and Synaptosomes: The Debate -- Quantal Release of Acetylcholine -- The Identification of ``Cholinergic´´ Neurons in the CNS -- Characterization and Classification of Cholinergic Neurons in the CNS -- References -- Chapter 2: Organization of the basal forebrain cholinergic system in the human brain -- Cholinergic Systems in the CNS -- Basal Forebrain Cholinergic Neurons and their Projections -- Inputs Into the Basal Forebrain Cholinergic Cell Groups -- Neurochemical Signatures of Basal Forebrain Cholinergic Neurons -- Cortical Cholinergic Axons -- Cortical Cholinergic Receptors and Acetylcholinesterase-Rich Cholinoceptive Neurons -- Functional Affiliations -- Acknowledgments -- References -- Chapter 3: The cholinergic synapses -- Introduction -- Composition and Basic Elements of the Cholinergic Synapse -- Cholinergic Synapses in Different Parts of the Nervous System -- Central nervous system transmission -- Different cholinergic receptors -- Cholinergic function in CNS diseases -- Alzheimer disease -- Parkinson disease -- Organophosphate poisoning -- Inflammation -- Cholinergic Synapses and Inflammation -- The Cholinergic Implications of Ischemic Stroke.
|
| 505 |
8 |
|
|a Viral vector-based gene delivery -- Small molecule modulators -- Encapsulated cell biodelivery -- Conclusion -- References -- Chapter 10: Memory network and cognitive reserve are associated with preserved and stimulated cholinergic neurotransmission -- Introduction -- The Cholinergic Impairment in Neurodegenerative Diseases -- Alzheimer disease spectrum -- Lewy body disease spectrum -- Imaging Biomarkers of the Cholinergic System -- Molecular neuroimaging -- Cholinergic imaging -- Imaging VAChT -- Imaging nAChR -- Imaging AChE -- FDG-PET -- Structural neuroimaging -- The Cholinergic Modulation of Memory and Attention Networks -- The cholinergic hypothesis of dementia and its revision -- Cognitive Reserve and Cholinergic Neurotransmission -- The concept of reserve -- Neural mechanism underlying cognitive reserve -- The concept of compensation -- The cognitive reserve and the cholinergic system -- Evidence in AD -- Evidence in LBD -- Conclusion -- References -- Chapter 11: Cholinergic therapy in Alzheimer disease -- Introduction -- Steps Leading to Regulatory Approval of ChEIs for AD -- Steps Leading to Clinical Use of ChEIs -- Clinical Benefit of ChEIs for Non-AD Dementias -- Limitations of Cholinergic Therapies for AD -- Efforts at Enhancing the Clinical Efficacy of ChEIs -- Lessons Learned From Optimal Testing and Use of New Drugs for AD -- References -- Chapter 12: CNS muscarinic receptors and muscarinic receptor agonists in Alzheimer disease treatment -- Introduction11Abbreviations used in the chapter are listed at the end of the chapter before References section. -- Muscarinic Acetylcholine Receptor Subtypes in the Brain -- Muscarinic Acetylcholine Receptor Subtypes in Peripheral Tissues -- Muscarinic Acetylcholine Receptor Subtype Expression in the Human Brain and AD -- M1 mAChR Is a Potential Therapeutic Target in AD.
|
| 505 |
8 |
|
|a M1 Agonists for Symptomatic Treatment and as Disease-Modifying (DM) Agents in AD -- Concluding Remarks and Outlook -- Competing interests -- References -- Chapter 13: The cholinotrophic system in Down syndrome -- Introduction -- Gestation of Primate Basal Forebrain Neurons -- Chemoanatomy of the CBF in the Neurotypical Brain -- Prenatal Development of the CBF System in DS -- Postnatal ChAT in the CBF in DS -- Abnormalities in CBF Target Sites in DS -- Cholinergic Muscarinic and Nicotinic Receptors in DS -- NGF Pathobiology in DS -- Trk Receptors in the CBF of DS -- p75NTR Receptors in the CBF of individuals with DS -- NGF Metabolic Pathways in DS -- Amyloid and the CBF Connectome in DS -- Intracellular Amyloid in CBF Connectome in DS -- Tau Pathology in the CBF system in DS -- Tau Pathology in Cholinergic Striatal Neurons in DS -- Amyloid Pathology and the Cholinergic Striatum in DS -- Spliceosome Dysfunction in Cortical Cholinergic Projection Sites in DS -- Gene Expression Within the CBF Connectome in DS -- Cholinotrophic Biomarkers for DS -- Cholinotrophic Treatment Strategies for DS -- NGF Treatment for DS -- Small Molecule Neurotrophins to Treat CBF Degeneration in DS -- Concluding Comments -- Future Directions -- Acknowledgments -- Conflict of interest -- References -- Chapter 14: The involvement of the cholinergic system in Parkinson disease -- Introduction -- Terminology -- Clinical approaches to investigate cholinergic dysfunction -- Clinical Correlates of Cholinergic Dysfunction in PD -- Motor Manifestations -- Cardinal motor symptoms and dyskinesia -- Gait problems and falls -- Freezing of gait -- Non-motor Manifestations -- Cognitive decline -- Pathologic studies -- Neuroimaging studies -- Neurophysiologic studies -- Neuropsychiatric symptoms -- Depression -- Visual hallucinations -- Sleep problems -- Olfactory dysfunction.
|
| 650 |
|
0 |
|a Nervous system
|x Diseases.
|
| 650 |
|
0 |
|a Cholinergic mechanisms.
|
| 650 |
|
2 |
|a Nervous System Diseases
|
| 650 |
|
6 |
|a Système nerveux
|x Maladies.
|
| 650 |
|
6 |
|a Systèmes cholinergiques.
|
| 655 |
|
7 |
|a Electronic books.
|2 local
|
| 700 |
1 |
|
|a Cuello, A. C.
|q (A. Claudio),
|e editor.
|1 https://id.oclc.org/worldcat/entity/E39PCjBFMFgxCrbKPhQ6HcMMRq
|
| 710 |
2 |
|
|a ScienceDirect (Online service)
|
| 856 |
4 |
0 |
|u http://proxy.library.tamu.edu/login?url=https://www.sciencedirect.com/science/handbooks/00729752/211
|z Connect to the full text of this electronic book
|t 0
|
| 955 |
|
|
|a Elsevier ScienceDirect 2026-2027
|
| 994 |
|
|
|a 92
|b TXA
|
| 999 |
f |
f |
|i c977abfb-215c-4d74-b505-7df9e0485c9b
|s ef37567b-6f7d-452e-9944-12623bfad124
|t 0
|
| 952 |
f |
f |
|a Texas A&M University
|b College Station
|c Electronic Resources
|s www_evans
|d Available Online
|t 0
|e RC346
|h Library of Congress classification
|
| 998 |
f |
f |
|a RC346
|t 0
|l Available Online
|